1
Clinical Trials associated with C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs(NCI)A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction With Standard Chemotherapy for Treatment of Lymphoma in Patients With HIV Infection
This pilot phase I trial studies the side effects and best dose of human immunodeficiency virus (HIV)-resistant gene modified stem cells in treating HIV-positive patients who are undergoing first-line treatment for Hodgkin or Non-Hodgkin Lymphoma. Stem cells are collected from the patient and HIV-resistance genes are placed into the stem cells. The stem cells are then re-infused into the patient. These genetically modified stem cells may help the body make cells that are resistant to HIV infection.
100 Clinical Results associated with C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs(NCI)
100 Translational Medicine associated with C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs(NCI)
100 Patents (Medical) associated with C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs(NCI)
100 Deals associated with C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs(NCI)